OptimizeRx Corporation

NasdaqCM:OPRX Stock Report

Market Cap: US$245.3m

OptimizeRx Management

Management criteria checks 4/4

OptimizeRx's CEO is Steve Silvestro, appointed in Oct 2023, has a tenure of 2.25 years. total yearly compensation is $973.13K, comprised of 41.1% salary and 58.9% bonuses, including company stock and options. directly owns 0.54% of the company’s shares, worth $1.32M. The average tenure of the management team and the board of directors is 2.8 years and 7.8 years respectively.

Key information

Steve Silvestro

Chief executive officer

US$973.1k

Total compensation

CEO salary percentage41.10%
CEO tenure2.3yrs
CEO ownership0.5%
Management average tenure2.8yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk

Nov 23
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk

Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?

Oct 07
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?

Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?

Aug 27
Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?

Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely

May 09
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
User avatar

A Subscription Model And EHR Network Will Reshape Healthcare

Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.

Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 06
Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value

We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt

Mar 08
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt

At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?

Feb 14
At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?

Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16
OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

May 31
Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

CEO Compensation Analysis

How has Steve Silvestro's remuneration changed compared to OptimizeRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

US$34k

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$973kUS$400k

-US$20m

Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$970kUS$385k

-US$18m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$2mUS$330k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$1mUS$330k

US$378k

Sep 30 2021n/an/a

US$1m

Jun 30 2021n/an/a

US$789k

Mar 31 2021n/an/a

-US$641k

Dec 31 2020US$866kUS$300k

-US$2m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$1mUS$189k

-US$3m

Compensation vs Market: Steve's total compensation ($USD973.13K) is below average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Silvestro (47 yo)

2.3yrs
Tenure
US$973,132
Compensation

Mr. Stephen L. Silvestro, also known as Steve, has been the Chief Executive Officer of OptimizeRx Corporation since June 20, 2025. He serves as President at OptimizeRx Corp. since October 2023 and served a...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Silvestro
President & CEO2.3yrsUS$973.13k0.54%
$ 1.3m
Edward Stelmakh
Chief Financial & Strategic Officer4.3yrsUS$1.01m0.43%
$ 1.1m
Brendan Merrell
Chief Operating Officerless than a yearno data0.053%
$ 131.1k
Marion Odence-Ford
Chief Legal & Administrative Officer4.9yrsUS$2.51m0.25%
$ 606.6k
Maira Alejandra
Media Relations Managerno datano datano data
Andrew D'Silva
Chief Business Officerless than a yearno data0.11%
$ 278.9k
Doug Besch
Chief Product Officer & CTO3.3yrsno data0.13%
$ 311.2k
Theresa Greco
Chief Commercial Officer2.3yrsno data0.17%
$ 411.0k
Heather Favazza
Controller7.3yrsno datano data
Sheryl Kearney
Human Resources Managerno datano datano data
2.8yrs
Average Tenure
52yo
Average Age

Experienced Management: OPRX's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Patrick Spangler
Independent Director7.8yrsUS$215.00k0.18%
$ 452.0k
Catherine Klema
Independent Director2yrsUS$206.50k0.063%
$ 154.7k
Gregory Wasson
Independent Director5.5yrsUS$195.00k0.25%
$ 622.7k
Ellen Vos
Independent Chairperson of the Board10.3yrsUS$249.00k0.34%
$ 826.1k
Jack Pinney
Head of Medical Advisory Board7.8yrsUS$112.91kno data
James Lang
Independent Director9yrsUS$204.00k2.09%
$ 5.1m
7.8yrs
Average Tenure
67.5yo
Average Age

Experienced Board: OPRX's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/11 12:21
End of Day Share Price 2026/01/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OptimizeRx Corporation is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserB. Riley Securities, Inc.
Anderson SchockB. Riley Securities, Inc.
Constantine DavidesCitizens JMP Securities, LLC